<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03832504</url>
  </required_header>
  <id_info>
    <org_study_id>ICM 2019-2425</org_study_id>
    <nct_id>NCT03832504</nct_id>
  </id_info>
  <brief_title>Identifying Strategies to Alleviate Cardiovascular Stress in Coronary Patients During Heatwaves</brief_title>
  <official_title>Identifying Optimal Cooling Strategies for Coronary Artery Disease Patients During Heatwaves</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the optimal cooling strategies to alleviate&#xD;
      cardiovascular strain of coronary artery disease individuals during a simulated North&#xD;
      American and Australian heatwave.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Globally, heatwaves are occurring more frequently, are of greater intensity and longer in&#xD;
      duration. The devastating health impacts of extreme heat are increasingly recognized,&#xD;
      particularly in vulnerable populations, such as adults with coronary artery disease (CAD).&#xD;
      While the most effective cooling strategy during a heatwave is the use of air conditioning&#xD;
      (AC), economical concerns can limit AC use among vulnerable populations. In addition,&#xD;
      widespread AC use places a significant burden on the electrical grid, causing brown-outs and&#xD;
      black-outs during periods of extreme heat.&#xD;
&#xD;
      Electric fans offer a cooling strategy with a 50-fold lower power requirement and cost&#xD;
      compared to AC. However, the efficacy of fan use during heat waves remains contentious. The&#xD;
      primary objective of this study is to identify the optimal cooling strategy to alleviate&#xD;
      cardiovascular strain of CAD patients exposed to typical North American heatwave conditions&#xD;
      (38°C with 60% relative humidity). The secondary objective is to identify the optimal cooling&#xD;
      strategy to alleviate cardiovascular strain of CAD patients exposed to typical Australian&#xD;
      heatwave conditions (46°C with 10% relative humidity).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Actual">June 23, 2021</completion_date>
  <primary_completion_date type="Actual">June 23, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate pressure product</measure>
    <time_frame>Change from baseline to the end of the 3 hour exposure</time_frame>
    <description>Rate pressure product, in beats per minute per mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body core temperature</measure>
    <time_frame>Change from baseline to the end of the 3 hour exposure</time_frame>
    <description>In degrees Celcius</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Skin temperature</measure>
    <time_frame>Change from baseline to the end of the 3 hour exposure</time_frame>
    <description>In degrees Celcius</description>
  </other_outcome>
  <other_outcome>
    <measure>Sweat loss</measure>
    <time_frame>Change from baseline to the end of the 3 hour exposure</time_frame>
    <description>In kilograms</description>
  </other_outcome>
  <other_outcome>
    <measure>Local sweat rate</measure>
    <time_frame>Measured continously during the 3 hour exposure</time_frame>
    <description>In mg per minute per cm2</description>
  </other_outcome>
  <other_outcome>
    <measure>Skin blood flow</measure>
    <time_frame>Measured continously during the 3 hour exposure.</time_frame>
    <description>In arbitrary perfusion units</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>38°C and 60% RH + No intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>38°C and 60% RH + Fan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>38°C and 60% RH + Skin wetting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>38°C and 60% RH + Fan + Skin wetting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tthe participant will enter an environmental chamber maintained at 38°C and 60% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>46°C and 10% RH + No intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>46°C and 10% RH + Skin wetting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participant will enter an environmental chamber maintained at 46°C and 10% relative humidity. The participant will remain within the environmental chamber and will rest in a seated position for 3 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>The participant will rest in a seated position.</description>
    <arm_group_label>38°C and 60% RH + No intervention</arm_group_label>
    <arm_group_label>46°C and 10% RH + No intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fan</intervention_name>
    <description>A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.</description>
    <arm_group_label>38°C and 60% RH + Fan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Skin Wetting</intervention_name>
    <description>Tap water (~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.</description>
    <arm_group_label>38°C and 60% RH + Skin wetting</arm_group_label>
    <arm_group_label>46°C and 10% RH + Skin wetting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fan + Skin wetting</intervention_name>
    <description>A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.</description>
    <arm_group_label>38°C and 60% RH + Fan + Skin wetting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of angiographic coronary disease (≥70% arterial diameter narrowing of at least&#xD;
             one major epicardial coronary artery) and/or prior coronary revascularization and/or&#xD;
             documented prior acute coronary syndrome and/or stable angina and/or perfusion defect&#xD;
             during exercise testing.&#xD;
&#xD;
          -  No CAD-related hospitalisations or changes in cardiac medications or change in pattern&#xD;
             of angina for at least 3 months prior to enrolment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index ≥35 kg/m2.&#xD;
&#xD;
          -  Currently undertaking estrogen therapy.&#xD;
&#xD;
          -  Evidence of current fluid and electrolyte disorders, anemia, abnormal thyroid&#xD;
             function, arrhythmias, diabetes, renal disease, liver disease, cerebrovascular&#xD;
             disease, significant pulmonary disease, endocrine abnormalities, significant cognitive&#xD;
             impairment, psychiatric disorder, substance abuse, degenerative neurological condition&#xD;
             or any other medical condition deemed to pose risk during the proposed experiments.&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;180/110 mmHg).&#xD;
&#xD;
          -  Recent (&lt;3 months) coronary bypass surgery.&#xD;
&#xD;
          -  Ejection fraction &lt;40% and/or clinical evidence/history of heart failure.&#xD;
&#xD;
          -  Significant valvular heart disease&#xD;
&#xD;
          -  Resting ECG abnormalities interfering with observation of ST segment changes during&#xD;
             testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>cardiovascular Prevention and rehabilitation Centre of the Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T1N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montreal Heart Institute</investigator_affiliation>
    <investigator_full_name>Daniel Gagnon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All individual data will be de-identified and available to the public through publications, media articles and conference presentations</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

